ASX Healthcare Stocks Positioning Well After Resurgence

These ASX healthcare companies are improving lives worldwide and offer compelling opportunities for investors who want to capture the sector’s future upside.

CSL Limited (ASX: CSL)

is a key global healthcare player that is involved in creation and distribution of biopharmaceutical products and vaccines.

The company reported revenue of US$15.56 billion for FY25 which grew by 5% and net profit after tax was US$3.09 billion which reflects a 17 % rise from last year.

EPS increased 10% to US$6.65 and free cash flow grew by 58% to US$2.86 billion.

CSL aims to demerge CSL Seqirus into a separate ASX-listed vaccine company by the end of FY26.

The company is set to deliver sustainable growth with the help of diversified revenue streams and expanding margins.

Cochlear Limited (ASX: COH)

advanced its leadership in implantable hearing solutions in FY25 helped by the launch of the Nucleus Nexa System which is the world’s first smart cochlear implant platform with upgradeable firmware, allowing recipients to access future innovations without needing a new implant.

The company rolled out new sound processors including the Kanso 3 Nexa and Baha 7 while also beginning pivotal studies on drug-eluting electrodes aimed at reducing inflammation and fibrosis in the inner ear to support better long-term stimulation quality.

For FY25, revenue reached a record $2.356 billion which grew by 4% and underlying net profit rose 1% to $392 million.

In FY26, Cochlear aims to help more than 60,000 people with a cochlear or acoustic implant and expects underlying net profit of $435–460 million which reflects a 11–17% growth.

ResMed Inc. (ASX: RMD)

had a great September quarter as net revenue for the was US$1.34 billion which is a 9% growth from last year.

The Sleep and Breathing Health segment is primarily responsible for ResMed’s performance as it generated revenue of US$1.17 billion which represents a growth of around10%.

The company’s software solutions help doctors track patient compliance which reduces hospital visits and focus on technology-driven healthcare is proving to be a key advantage for the company.

Due to the rising awareness about sleep disorders and the growing need for digital healthcare solutions, ResMed’s future looks bright and presents a compelling opportunity for investors.

Sonic Healthcare Limited (ASX: SHL)

delivered a solid FY25 as group revenue rose to $9.6 billion and net profit reached $514 million supported by 5% organic revenue growth and a 40 basis-point expansion in normalised margins.

The company advanced key growth initiatives such as the LADR Laboratory Group acquisition in Germany which generates €370 million revenue and €50 million EBITDA.

Radiology delivered 10% organic revenue growth helped by demand for higher-value imaging modalities and seven new site openings.

Sonic expects earnings growth to accelerate in FY26 as synergies begin to flow from recent acquisitions in Switzerland, Germany and the USA along with strong organic growth across its global markets.

The company has issued EBITDA guidance for FY26 of $1.87–$1.95 billion which represents up to 13% growth.

(Source: Company Reports)